Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Natalie C. Holles
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 113
- Beta
- 0.40
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 8.96
Financials
Net Income
$-45.64MEBITDA
$-48.07MFree Cash Flow
$-31.82MEPS (diluted)
$-0.48Shares Outstanding (diluted)
94.86M+174.1%Operating Expenses
$48.07MCash & Debt
$323.84MReturn of Capital
$39.09MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-106.19M | $-1.76 |
| 2024 | $0.00 | $-86.92M | $-1.75 |
| 2023 | $0.00 | $-76.41M | $-1.93 |
| 2022 | $0.00 | $-58.76M | $-1.96 |
| 2021 | $0.00 | $-35.25M | $-1.58 |
| 2020 | $0.00 | $-22.21M | $-1.03 |
| 2019 | $0.00 | $-24.20M | $-0.01 |
Valuation
AURAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+0.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·19d ago·Positive
Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Aura Biosciences to Participate in Upcoming Investor Conference BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval Aura Biosciences, Inc. is focused on late-stage development of Bel-sar for early choroidal melanoma, addressing significant unmet medical needs. The Phase 3 CoMpass trial is fully enrolled, with topline data expected in 2H 2027; Phase 2 data showed 80% tumor control and strong safety. A recent C-suite overhaul and $299M capital raise position AURA to prioritize ocular oncology and streamline operations, with funding
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.37 per share
Typical surprise -17.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.48 vs $-0.38miss
- Mon, May 11$-0.50 vs $-0.40miss
- Mon, Mar 30$-0.37 vs $-0.43beat
- Thu, Nov 13$-0.40 vs $-0.46beat
- Wed, Aug 13$-0.47 vs $-0.49beat
- Thu, May 15$-0.55 vs $-0.47miss
Estimates and results for AURA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AURA officers and directors.
- Bought
- $429k
- Sold
- $40.4m
4 trades
22 trades
- Gibney Anthony Ssold
- Matrix Capital Management Company, Lpsold
- Kilroy Conorsold
- Kilroy Conorsold
- Plavsic Marksold
- Hopkins Janet Jillsold
- Elazzouzi Amysold
- De Los Pinos Elisabetsold
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AURA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.